391 results on '"Ingram, Wendy"'
Search Results
2. Adding web-based support to exercise referral schemes improves symptoms of depression in people with elevated depressive symptoms: A secondary analysis of the e-coachER randomised controlled trial
- Author
-
Lambert, Jeffrey, Taylor, Adrian, Streeter, Adam, Greaves, Colin, Ingram, Wendy M., Dean, Sarah, Jolly, Kate, Mutrie, Nanette, Price, Lisa, and Campbell, John
- Published
- 2023
- Full Text
- View/download PDF
3. Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
- Author
-
Taylor Adrian H, Thompson Tom P, Streeter Adam, Chynoweth Jade, Snowsill Tristan, Ingram Wendy, Ussher Michael, Aveyard Paul, Murray Rachael L, Harris Tess, Green Colin, Horrell Jane, Callaghan Lynne, Greaves Colin J, Price Lisa, Cartwright Lucy, Wilks Jonny, Campbell Sarah, Preece Dan, and Creanor Siobhan
- Subjects
smoking ,reduction ,quitting ,abstinence ,physical activity ,exercise ,accelerometer ,adult ,cost-benefit analysis ,behaviour change ,motivational support ,motivational interviewing ,mediation ,primary health care ,process evaluation ,qualitative ,quality of life ,quality-adjusted life-years ,self-determination theory ,self-monitoring ,goal-setting ,rct ,Medical technology ,R855-855.5 - Abstract
Background: Physical activity can support smoking cessation for smokers wanting to quit, but there have been no studies on supporting smokers wanting only to reduce. More broadly, the effect of motivational support for such smokers is unclear. Objectives The objectives were to determine if motivational support to increase physical activity and reduce smoking for smokers not wanting to immediately quit helps reduce smoking and increase abstinence and physical activity, and to determine if this intervention is cost-effective. Design This was a multicentred, two-arm, parallel-group, randomised (1 : 1) controlled superiority trial with accompanying trial-based and model-based economic evaluations, and a process evaluation. Setting and participants Participants from health and other community settings in four English cities received either the intervention (n = 457) or usual support (n = 458). Intervention The intervention consisted of up to eight face-to-face or telephone behavioural support sessions to reduce smoking and increase physical activity. Main outcome measures The main outcome measures were carbon monoxide-verified 6- and 12-month floating prolonged abstinence (primary outcome), self-reported number of cigarettes smoked per day, number of quit attempts and carbon monoxide-verified abstinence at 3 and 9 months. Furthermore, self-reported (3 and 9 months) and accelerometer-recorded (3 months) physical activity data were gathered. Process items, intervention costs and cost-effectiveness were also assessed. Results The average age of the sample was 49.8 years, and participants were predominantly from areas with socioeconomic deprivation and were moderately heavy smokers. The intervention was delivered with good fidelity. Few participants achieved carbon monoxide-verified 6-month prolonged abstinence [nine (2.0%) in the intervention group and four (0.9%) in the control group; adjusted odds ratio 2.30 (95% confidence interval 0.70 to 7.56)] or 12-month prolonged abstinence [six (1.3%) in the intervention group and one (0.2%) in the control group; adjusted odds ratio 6.33 (95% confidence interval 0.76 to 53.10)]. At 3 months, the intervention participants smoked fewer cigarettes than the control participants (21.1 vs. 26.8 per day). Intervention participants were more likely to reduce cigarettes by ≥ 50% by 3 months [18.9% vs. 10.5%; adjusted odds ratio 1.98 (95% confidence interval 1.35 to 2.90] and 9 months [14.4% vs. 10.0%; adjusted odds ratio 1.52 (95% confidence interval 1.01 to 2.29)], and reported more moderate-to-vigorous physical activity at 3 months [adjusted weekly mean difference of 81.61 minutes (95% confidence interval 28.75 to 134.47 minutes)], but not at 9 months. Increased physical activity did not mediate intervention effects on smoking. The intervention positively influenced most smoking and physical activity beliefs, with some intervention effects mediating changes in smoking and physical activity outcomes. The average intervention cost was estimated to be £239.18 per person, with an overall additional cost of £173.50 (95% confidence interval −£353.82 to £513.77) when considering intervention and health-care costs. The 1.1% absolute between-group difference in carbon monoxide-verified 6-month prolonged abstinence provided a small gain in lifetime quality-adjusted life-years (0.006), and a minimal saving in lifetime health-care costs (net saving £236). Conclusions There was no evidence that behavioural support for smoking reduction and increased physical activity led to meaningful increases in prolonged abstinence among smokers with no immediate plans to quit smoking. The intervention is not cost-effective. Limitations Prolonged abstinence rates were much lower than expected, meaning that the trial was underpowered to provide confidence that the intervention doubled prolonged abstinence. Future work Further research should explore the effects of the present intervention to support smokers who want to reduce prior to quitting, and/or extend the support available for prolonged reduction and abstinence. Trial registration This trial is registered as ISRCTN47776579. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 27, No. 4. See the NIHR Journals Library website for further project information. Plain language summary: NHS pharmacological and behavioural support helps smokers wanting to quit, and physical activity may also help. It is unclear if behavioural support for those not ready to quit may lead to more quit attempts and abstinence from smoking. A total of 915 smokers who wanted to reduce their smoking, but who had not yet quit, were recruited and randomised to receive an intervention or brief support as usual (brief advice to quit), in Plymouth, London, Oxford and Nottingham. The intervention involved up to eight sessions (by telephone or in person) of motivational support to reduce smoking and increase physical activity (and more sessions to support a quit attempt). Participants self-reported smoking and physical activity information at the start of the trial and after 3 and 9 months. Self-reported quitters confirmed their abstinence with a biochemical test of expired air or saliva. Our main interest was in whether or not the groups differed in the proportion who remained abstinent for at least 6 months. Overall, only 1–2% remained abstinent for 6 months. Although it appeared that a greater proportion did so after receiving the intervention, because few participants were abstinent, the results are not conclusive. However, the intervention had beneficial effects on less rigorous outcomes, including a reduction in the self-reported number of cigarettes smoked, and a greater proportion of intervention than control participants with self-reported and biochemically verified abstinence at 3 months. The intervention also helped participants to reduce, by at least half, the number of cigarettes they smoked at 3 and 9 months, and to report more physical activity, but only at 3 months. Despite reasonable intervention engagement and some short-term changes in smoking and physical activity, the trial does not provide evidence that this intervention would help smokers to quit for at least 6 months nor would it be cost-effective, with an average cost of £239 per smoker. Scientific summary: Background Behavioural support to aid smoking cessation is an effective and cost-effective intervention for smokers wanting to quit. Motivational support can reduce smoking, with greater reductions leading to successful quitting, but the evidence is fairly weak for those not wanting to immediately quit. Smoking reduction studies may involve two types of smokers: (1) those who want to quit and are willing to reduce first rather than quit abruptly and (2) those who do not want to quit (immediately) but are interested in smoking reduction or harm reduction. At least four studies have investigated the effects of behavioural support for smokers wanting to reduce but not quit, and provide imprecise or no evidence of effects on smoking reduction, quitting and sustained abstinence. Exercise has been shown to aid smoking cessation for those wanting to quit, but there is only exploratory evidence that promoting physical activity (PA) and supporting smoking reduction can facilitate smoking reduction and quitting. A definitive study is needed to determine the effectiveness and cost-effectiveness of behavioural support for smoking reduction and increasing PA, on smoking outcomes, especially prolonged, carbon monoxide-verified smoking abstinence. Objectives The overall aim of the Trial of physical Activity-assisted Reduction of Smoking (TARS) was to determine if adding a motivational intervention to reduce smoking and increase PA to usual support was more effective and cost-effective in facilitating carbon monoxide-verified 6-month floating prolonged abstinence. The specific research questions were as follows. Compared with usual support, did the TARS intervention: increase the proportion of participants achieving carbon monoxide-verified 6-month floating prolonged abstinence at 9 months post baseline? increase the proportion of participants reporting a ≥ 50% reduction in the number of cigarettes smoked (between baseline and 3 months, and baseline and 9 months)? increase the proportion of participants achieving carbon monoxide-verified 12-month floating prolonged abstinence at 15 months post baseline? increase the proportion of participants achieving self-reported and carbon monoxide-verified point prevalence abstinence at 3 and 9 months post baseline? increase self-reported PA at 3 and 9 months post baseline, and accelerometer-assessed PA at 3 months post baseline? improve body mass index, quality of life, sleep, cigarette cravings and other beliefs about smoking and PA at 3 and 9 months post baseline? What were the intervention, health-care and social care costs, compared with support as usual, at 9 months post baseline? Was the intervention cost-effective, compared with usual support, (1) at 9 months, and (2) over a longer-term/lifetime horizon? Were the trial methods and intervention acceptable and feasible, based on an embedded internal pilot phase? Did the intervention demonstrate good fidelity (design, training, delivery, receipt and enactment) and acceptability and what were the mechanisms of action of the intervention? Methods The study involved a multicentred, parallel, two-group, individually randomised controlled, superiority trial with a mixed-methods embedded process evaluation and economic evaluations. Recruitment took place over 16 months from January 2018, with follow-up assessments ending in October 2020 (with only minimal overlap with COVID-19 restrictions) around four English cities: Plymouth, Nottingham, London and Oxford. Intervention participants were offered up to eight face-to-face or telephone behavioural support sessions to reduce smoking and increase PA, with up to six additional sessions if a participant wanted support with cessation. Substantial patient and public involvement supported both the development and evaluation of a pilot trial of the intervention, and adaptations for the present intervention. An intervention manual underpinned the training and remote supervision of eight health trainers (HTs) across four sites, and all aspects of intervention fidelity (design, training, receipt, delivery and enactment) were assessed. The client-centred intervention was informed by motivational interviewing and linked to self-determination theory. It aimed to empower participants to decide what support they required, and where, when and for how long, and, if the participant became ready to quit, to provide appropriate support. Control participants received brief advice on smoking cessation. Participants were recruited from primary and secondary care and community settings. Participants were adult smokers (≥ 18 years) who smoked ≥ 10 cigarettes per day (for at least 1 year), who wanted to reduce smoking but not quit immediately. Smokers were ineligible if they were unable to engage in at least 15 minutes of moderate-intensity PA, had any illness or injury that might be exacerbated by exercise, or were unable to engage in the trial and/or the intervention because of a language barrier or for other reasons. Following screening and consent, participants completed baseline assessments face to face or via telephone. At 3 and 9 months post baseline, participants were posted a questionnaire (and an accelerometer at 3 months for a random sample). Participants reporting having made a quit attempt and not having smoked at follow-up were invited to complete a biochemical verification of abstinence. Most did this with a carbon monoxide expired air test, but a few were posted a saliva cotinine test kit late in the trial as a result of COVID-19 restrictions. Those with carbon monoxide-verified abstinence at 9 months were also followed up at 15 months. The primary outcome was carbon monoxide-verified 6-month floating prolonged (i.e. with no fixed quit date) abstinence between 3 and 9 months. Other smoking measures were carbon monoxide-verified 12-month floating prolonged abstinence, point prevalence self-reported abstinence and number of cigarettes smoked per day, and carbon monoxide-verified abstinence and number of quit attempts at both 3 and 9 months. Analyses of smoking abstinence outcomes were in line with the Russell Standard, with non-responders assumed to be still smoking. Self-reported (3 and 9 months) and accelerometer-recorded (3 months) PA, body mass index, sleep and quality of life were also assessed at 3 and 9 months. The embedded mixed-methods process evaluation was split into two phases: (1) an initial evaluation linked to the internal pilot phase and (2) the subsequent main trial phase, with four workstreams as follows – (1) data related to levels of intervention engagement; (2) assessment of intervention delivery, receipt and enactment fidelity, using survey items related to the intervention logic model and recorded intervention sessions; (3) mediation analyses of changes in PA and process measures on outcomes; and (4) an embedded qualitative study with HT and intervention participant interviews. The health economic evaluation included an estimation of the cost of delivering the intervention from data collected during the trial, supplemented by investigator estimates. A trial-based economic evaluation was conducted using patient-reported resource use and health-related quality of life (EuroQol-5 Dimensions, five-level version), collected in questionnaire booklets at baseline and at 3 and 9 months post randomisation. Aggregate costs and quality-adjusted life-years (QALYs) over a 9-month time horizon were estimated and regression methods were used to adjust for potential confounders. A decision-analytic model was developed following a review of the existing literature. Smoking cessation rates were assumed to affect rates of coronary obstructive pulmonary disease, coronary heart disease, stroke and lung cancer, as well as quality of life and other smoking-related causes of mortality. Lifetime costs and QALYs were estimated. Results The sample (n = 915) had a mean age of 49.8 [standard deviation (SD) 13.9] years; 55% were female and 85% identified as white. Sixty per cent lived within one of the four highest-ranked deciles for social deprivation. They initially smoked an average of 18.0 cigarettes daily, with 77.68% smoking within 30 minutes of waking, and reported doing a median of 337 minutes of moderate to vigorous physical activity (MVPA) weekly. Primary analysis Using the Russell Standard, assuming missing participant data at follow-up implied continued smoking, 0.9% (n = 4) of control and 2.0% (n = 9) of intervention participants achieved carbon monoxide-verified 6-month floating prolonged abstinence between 3 and 9 months. This difference was not statistically significant [fully adjusted estimated odds ratio 2.30, 95% confidence interval (CI) 0.70 to 7.56; p = 0.169]. Including participants who achieved the outcome between 9 and 15 months increased this to 2.2% (n = 10) and 3.1% (n = 14) in the control and intervention groups, respectively, which was also not statistically significantly different (fully adjusted estimated odds ratio 1.43, 95% CI 0.62 to 3.26; p = 0.398). For the 19 and 20 participants followed up at 15 months, 0.2% (n = 1) and 1.3% (n = 6) of the overall control and intervention groups, respectively, achieved carbon monoxide-verified 12-month floating prolonged abstinence, which was also not statistically significantly different (fully adjusted estimated odds ratio 6.3, 95% CI 0.8 to 53.1; p = 0.089). Secondary outcomes The intervention had weak effects on self-reported 7-day point prevalence abstinence at 3 months (5.5% vs. 2.9%, adjusted odds ratio 1.99, 95% CI 1.00 to 3.94; p = 0.049), but there was no evidence of a statistically significant effect on carbon monoxide-verified point prevalence abstinence at 3 months (3.7% vs. 1.8%, adjusted odds ratio 2.19, 95% CI 0.93 to 5.14; p = 0.071). Nor was there an intervention effect at 9 or 15 months, compared with control, for either of these outcomes. The intervention group reported smoking fewer cigarettes daily than the control group at 3 months (adjusted mean difference –5.62, 95% CI –9.80 to –1.44; p = 0.009), but not at 9 months (adjusted mean difference 0.95, 95% CI –5.37 to 3.46; p = 0.671). A greater proportion of intervention participants reported having reduced their daily number of cigarettes smoked by at least 50%, up to 3 months (18.9% vs. 10.5%, adjusted odds ratio 1.98, 95% CI 1.35 to 2.90; p
- Published
- 2023
- Full Text
- View/download PDF
4. A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol
- Author
-
Swancutt, Dawn, Tarrant, Mark, Ingram, Wendy, Baldrey, Sarah, Burns, Lorna, Byng, Richard, Calitri, Raff, Creanor, Siobhan, Dean, Sarah, Evans, Lucy, Gill, Laura, Goodwin, Elizabeth, Hawkins, Lily, Hayward, Chris, Hind, Sarah, Hollands, Laura, Hosking, Joanne, Lloyd, Jenny, Moghadam, Shokraneh, Neilens, Helen, O’Kane, Mary, Perry, Steve, Sheaff, Rod, Spencer, Anne, Taylor, Adrian, Ward, Thomas, Watkins, Ross, Wilding, John, and Pinkney, Jonathan
- Published
- 2022
- Full Text
- View/download PDF
5. A process evaluation, with mediation analysis, of a web-based intervention to augment primary care exercise referral schemes: the e-coachER randomised controlled trial
- Author
-
Lambert, Jeffrey, Taylor, Adrian, Streeter, Adam, Greaves, Colin, Ingram, Wendy M., Dean, Sarah, Jolly, Kate, Mutrie, Nanette, Taylor, Rod S., Yardley, Lucy, Price, Lisa, and Campbell, John
- Published
- 2022
- Full Text
- View/download PDF
6. Informatics Technologies in the Diagnosis and Treatment of Mental Health Conditions
- Author
-
Ingram, Wendy Marie, Khanna, Rahul, Weston, Cody, Tenenbaum, Jessica D., editor, and Ranallo, Piper A., editor
- Published
- 2021
- Full Text
- View/download PDF
7. In-person and remote recruitment of people with dementia into a primary care-based cluster randomised controlled trial: lessons from the Dementia PersonAlised Care Team (D-PACT) feasibility study
- Author
-
Oh, Tomasina M., primary, Batool, Saqba, additional, Musicha, Crispin, additional, Greene, Leanne, additional, Wheat, Hannah, additional, Smith, Lorna, additional, Griffiths, Sarah, additional, Gude, Alex, additional, Weston, Lauren, additional, Shafi, Hannah, additional, Stevens, Kara, additional, Sutcliffe, Caroline, additional, Taylor, Wendy, additional, Ingram, Wendy, additional, Hussain, Basharat, additional, Clarkson, Paul, additional, Sherriff, Ian, additional, Ukoumunne, Obioha, additional, Creanor, Siobhan, additional, and Byng, Richard, additional
- Published
- 2024
- Full Text
- View/download PDF
8. Safety and Efficacy of Axatilimab in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
- Author
-
DeFilipp, Zachariah, primary, Lee, Stephanie J., additional, Pusic, Dr. Iskra, additional, Arai, Sally, additional, Pérez-Simón, José Antonio, additional, Gandhi, Arpita P, additional, Choe, Hannah, additional, Ingram, Wendy, additional, Loron, Sandrine, additional, Zaid, Mohammad I Abu, additional, White, Jennifer, additional, Popradi, Gizelle, additional, Salhotra, Amandeep, additional, Ciceri, Fabio, additional, Radojcic, Vedran, additional, O'Toole, Timothy, additional, Tian, Chuan, additional, Ordentlich, Peter, additional, Hamadani, Mehdi, additional, Cutler, Corey, additional, Wolff, Daniel, additional, and Kitko, Carrie L., additional
- Published
- 2024
- Full Text
- View/download PDF
9. Peripartum complications associated with obsessive compulsive disorder exacerbation during pregnancy
- Author
-
Holingue, Calliope, Samuels, Jack, Guglielmi, Valeria, Ingram, Wendy, Nestadt, Gerald, and Nestadt, Paul S.
- Published
- 2021
- Full Text
- View/download PDF
10. Neurological updates: neurological complications of CAR-T therapy
- Author
-
Tallantyre, Emma C., Evans, Nia A., Parry-Jones, Jack, Morgan, Matt P. G., Jones, Ceri H., and Ingram, Wendy
- Published
- 2021
- Full Text
- View/download PDF
11. Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia
- Author
-
Wright, Rachel, Oremek, Maximilian, Davies, David, Kewley, Caitlin, Singh, Alyssa, Taitt, Nathaniel, Kempshall, Emma, Wilson, Keith, and Ingram, Wendy
- Published
- 2020
- Full Text
- View/download PDF
12. Defining major depressive disorder cohorts using the EHR: Multiple phenotypes based on ICD-9 codes and medication orders
- Author
-
Ingram, Wendy Marie, Baker, Anna M., Bauer, Christopher R., Brown, Jason P., Goes, Fernando S., Larson, Sharon, and Zandi, Peter P.
- Published
- 2020
- Full Text
- View/download PDF
13. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
- Author
-
Thompson, Eric M, Hielscher, Thomas, Bouffet, Eric, Remke, Marc, Luu, Betty, Gururangan, Sridharan, McLendon, Roger E, Bigner, Darell D, Lipp, Eric S, Perreault, Sebastien, Cho, Yoon-Jae, Grant, Gerald, Kim, Seung-Ki, Lee, Ji Yeoun, Rao, Amulya A Nageswara, Giannini, Caterina, Li, Kay Ka Wai, Ng, Ho-Keung, Yao, Yu, Kumabe, Toshihiro, Tominaga, Teiji, Grajkowska, Wieslawa A, Perek-Polnik, Marta, Low, David CY, Seow, Wan Tew, Chang, Kenneth TE, Mora, Jaume, Pollack, Ian F, Hamilton, Ronald L, Leary, Sarah, Moore, Andrew S, Ingram, Wendy J, Hallahan, Andrew R, Jouvet, Anne, Fèvre-Montange, Michelle, Vasiljevic, Alexandre, Faure-Conter, Cecile, Shofuda, Tomoko, Kagawa, Naoki, Hashimoto, Naoya, Jabado, Nada, Weil, Alexander G, Gayden, Tenzin, Wataya, Takafumi, Shalaby, Tarek, Grotzer, Michael, Zitterbart, Karel, Sterba, Jaroslav, Kren, Leos, Hortobágyi, Tibor, Klekner, Almos, László, Bognár, Pócza, Tímea, Hauser, Peter, Schüller, Ulrich, Jung, Shin, Jang, Woo-Youl, French, Pim J, Kros, Johan M, van Veelen, Marie-Lise C, Massimi, Luca, Leonard, Jeffrey R, Rubin, Joshua B, Vibhakar, Rajeev, Chambless, Lola B, Cooper, Michael K, Thompson, Reid C, Faria, Claudia C, Carvalho, Alice, Nunes, Sofia, Pimentel, José, Fan, Xing, Muraszko, Karin M, López-Aguilar, Enrique, Lyden, David, Garzia, Livia, Shih, David JH, Kijima, Noriyuki, Schneider, Christian, Adamski, Jennifer, Northcott, Paul A, Kool, Marcel, Jones, David TW, Chan, Jennifer A, Nikolic, Ana, Garre, Maria Luisa, Van Meir, Erwin G, Osuka, Satoru, Olson, Jeffrey J, Jahangiri, Arman, Castro, Brandyn A, Gupta, Nalin, Weiss, William A, Moxon-Emre, Iska, Mabbott, Donald J, Lassaletta, Alvaro, Hawkins, Cynthia E, Tabori, Uri, Drake, James, and Kulkarni, Abhaya
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Oncology and Carcinogenesis ,Brain Disorders ,Rare Diseases ,Brain Cancer ,Pediatric Research Initiative ,Pediatric ,Cancer ,Adult ,Brain Neoplasms ,Canada ,Child ,Child ,Preschool ,Combined Modality Therapy ,Disease Progression ,Disease-Free Survival ,Female ,Humans ,Infant ,Magnetic Resonance Imaging ,Male ,Medulloblastoma ,Prognosis ,Retrospective Studies ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundPatients with incomplete surgical resection of medulloblastoma are controversially regarded as having a marker of high-risk disease, which leads to patients undergoing aggressive surgical resections, so-called second-look surgeries, and intensified chemoradiotherapy. All previous studies assessing the clinical importance of extent of resection have not accounted for molecular subgroup. We analysed the prognostic value of extent of resection in a subgroup-specific manner.MethodsWe retrospectively identified patients who had a histological diagnosis of medulloblastoma and complete data about extent of resection and survival from centres participating in the Medulloblastoma Advanced Genomics International Consortium. We collected from resections done between April, 1997, and February, 2013, at 35 international institutions. We established medulloblastoma subgroup affiliation by gene expression profiling on frozen or formalin-fixed paraffin-embedded tissues. We classified extent of resection on the basis of postoperative imaging as gross total resection (no residual tumour), near-total resection (30 Gy vs no craniospinal irradiation). The primary analysis outcome was the effect of extent of resection by molecular subgroup and the effects of other clinical variables on overall and progression-free survival.FindingsWe included 787 patients with medulloblastoma (86 with WNT tumours, 242 with SHH tumours, 163 with group 3 tumours, and 296 with group 4 tumours) in our multivariable Cox models of progression-free and overall survival. We found that the prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. We identified a progression-free survival benefit for gross total resection over sub-total resection (hazard ratio [HR] 1·45, 95% CI 1·07-1·96, p=0·16) but no overall survival benefit (HR 1·23, 0·87-1·72, p=0·24). We saw no progression-free survival or overall survival benefit for gross total resection compared with near-total resection (HR 1·05, 0·71-1·53, p=0·8158 for progression-free survival and HR 1·14, 0·75-1·72, p=0·55 for overall survival). No significant survival benefit existed for greater extent of resection for patients with WNT, SHH, or group 3 tumours (HR 1·03, 0·67-1·58, p=0·89 for sub-total resection vs gross total resection). For patients with group 4 tumours, gross total resection conferred a benefit to progression-free survival compared with sub-total resection (HR 1·97, 1·22-3·17, p=0·0056), especially for those with metastatic disease (HR 2·22, 1·00-4·93, p=0·050). However, gross total resection had no effect on overall survival compared with sub-total resection in patients with group 4 tumours (HR 1·67, 0·93-2·99, p=0·084).InterpretationThe prognostic benefit of increased extent of resection for patients with medulloblastoma is attenuated after molecular subgroup affiliation is taken into account. Although maximum safe surgical resection should remain the standard of care, surgical removal of small residual portions of medulloblastoma is not recommended when the likelihood of neurological morbidity is high because there is no definitive benefit to gross total resection compared with near-total resection.FundingCanadian Cancer Society Research Institute, Terry Fox Research Institute, Canadian Institutes of Health Research, National Institutes of Health, Pediatric Brain Tumor Foundation, and the Garron Family Chair in Childhood Cancer Research.
- Published
- 2016
14. Divergent clonal selection dominates medulloblastoma at recurrence
- Author
-
Morrissy, A Sorana, Garzia, Livia, Shih, David JH, Zuyderduyn, Scott, Huang, Xi, Skowron, Patryk, Remke, Marc, Cavalli, Florence MG, Ramaswamy, Vijay, Lindsay, Patricia E, Jelveh, Salomeh, Donovan, Laura K, Wang, Xin, Luu, Betty, Zayne, Kory, Li, Yisu, Mayoh, Chelsea, Thiessen, Nina, Mercier, Eloi, Mungall, Karen L, Ma, Yusanne, Tse, Kane, Zeng, Thomas, Shumansky, Karey, Roth, Andrew JL, Shah, Sohrab, Farooq, Hamza, Kijima, Noriyuki, Holgado, Borja L, Lee, John JY, Matan-Lithwick, Stuart, Liu, Jessica, Mack, Stephen C, Manno, Alex, Michealraj, KA, Nor, Carolina, Peacock, John, Qin, Lei, Reimand, Juri, Rolider, Adi, Thompson, Yuan Y, Wu, Xiaochong, Pugh, Trevor, Ally, Adrian, Bilenky, Mikhail, Butterfield, Yaron SN, Carlsen, Rebecca, Cheng, Young, Chuah, Eric, Corbett, Richard D, Dhalla, Noreen, He, An, Lee, Darlene, Li, Haiyan I, Long, William, Mayo, Michael, Plettner, Patrick, Qian, Jenny Q, Schein, Jacqueline E, Tam, Angela, Wong, Tina, Birol, Inanc, Zhao, Yongjun, Faria, Claudia C, Pimentel, José, Nunes, Sofia, Shalaby, Tarek, Grotzer, Michael, Pollack, Ian F, Hamilton, Ronald L, Li, Xiao-Nan, Bendel, Anne E, Fults, Daniel W, Walter, Andrew W, Kumabe, Toshihiro, Tominaga, Teiji, Collins, V Peter, Cho, Yoon-Jae, Hoffman, Caitlin, Lyden, David, Wisoff, Jeffrey H, Garvin, James H, Stearns, Duncan S, Massimi, Luca, Schüller, Ulrich, Sterba, Jaroslav, Zitterbart, Karel, Puget, Stephanie, Ayrault, Olivier, Dunn, Sandra E, Tirapelli, Daniela PC, Carlotti, Carlos G, Wheeler, Helen, Hallahan, Andrew R, Ingram, Wendy, MacDonald, Tobey J, Olson, Jeffrey J, Van Meir, Erwin G, Lee, Ji-Yeoun, and Wang, Kyu-Chang
- Subjects
Pediatric ,Biotechnology ,Genetics ,Brain Disorders ,Human Genome ,Brain Cancer ,Rare Diseases ,Cancer ,Animals ,Cerebellar Neoplasms ,Clone Cells ,Craniospinal Irradiation ,DNA Mutational Analysis ,Disease Models ,Animal ,Drosophila melanogaster ,Female ,Genome ,Human ,Humans ,Male ,Medulloblastoma ,Mice ,Molecular Targeted Therapy ,Neoplasm Recurrence ,Local ,Radiotherapy ,Image-Guided ,Selection ,Genetic ,Signal Transduction ,Xenograft Model Antitumor Assays ,General Science & Technology - Abstract
The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon-driven, functional genomic mouse model of medulloblastoma with 'humanized' in vivo therapy (microneurosurgical tumour resection followed by multi-fractionated, image-guided radiotherapy). Genetic events in recurrent murine medulloblastoma exhibit a very poor overlap with those in matched murine diagnostic samples (
- Published
- 2016
15. International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic)
- Author
-
Soda, Takahiro, McLoughlin, Declan M., Clark, Scott R., Oltedal, Leif, Kessler, Ute, Haavik, Jan, Bousman, Chad, Smith, Daniel J., Bioque, Miquel, Clements, Caitlin C., Loo, Colleen, Vila-Rodriguez, Fidel, Minelli, Alessandra, Mickey, Brian J., Milev, Roumen, Docherty, Anna R., Langan Martin, Julie, Achtyes, Eric D., Arolt, Volker, Redlich, Ronny, Dannlowski, Udo, Cardoner, Narcis, Clare, Emily, Craddock, Nick, Di Florio, Arianna, Dmitrzak-Weglarz, Monika, Forty, Liz, Gordon-Smith, Katherine, Husain, Mustafa, Ingram, Wendy M., Jones, Lisa, Jones, Ian, Juruena, Mario, Kirov, George, Landén, Mikael, Müller, Daniel J., Nordensköld, Axel, Pålsson, Erik, Paul, Meethu, Permoda, Agnieszka, Pliszka, Bartlomiej, Rea, Jamie, Schubert, Klaus O., Sonnen, Joshua A., Soria, Virginia, Stageman, Will, Takamiya, Akihiro, Urretavizacaya, Mikel, Watson, Stuart, Zavorotny, Maxim, Young, Allan H., Vieta, Eduard, Rybakowski, Janusz K., Gennarelli, Massimo, Zandi, Peter P., Sullivan, Patrick F., and Baune, Bernhard T.
- Published
- 2020
- Full Text
- View/download PDF
16. Mice Infected with Low-virulence Strains of Toxoplasma gondii Lose their Innate Aversion to Cat Urine, Even after Extensive Parasite Clearance
- Author
-
Ingram, Wendy Marie, Goodrich, Leeanne M, Robey, Ellen A, and Eisen, Michael B
- Subjects
Quantitative Biology - Tissues and Organs ,Quantitative Biology - Neurons and Cognition - Abstract
Toxoplasma gondii chronic infection in rodent secondary hosts has been reported to lead to a loss of innate, hard-wired fear toward cats, its primary host. However the generality of this response across T. gondii strains and the underlying mechanism for this pathogen mediated behavioral change remain unknown. To begin exploring these questions, we evaluated the effects of infection with two previously uninvestigated isolates from the three major North American clonal lineages of T. gondii, Type III and an attenuated strain of Type I. Using an hour-long open field activity assay optimized for this purpose, we measured mouse aversion toward predator and non-predator urines. We show that loss of innate aversion of cat urine is a general trait caused by infection with any of the three major clonal lineages of parasite. Surprisingly, we found that infection with the attenuated Type I parasite results in sustained loss of aversion at times post infection when neither parasite nor ongoing brain inflammation were detectable. This suggests that T. gondii-mediated interruption of mouse innate aversion toward cat urine may occur during early acute infection in a permanent manner, not requiring persistence of parasitecysts or continuing brain inflammation., Comment: 14 pages, 3 figures
- Published
- 2013
- Full Text
- View/download PDF
17. SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria
- Author
-
Griffin, Morag, primary, Eikema, Dirk-Jan, additional, Verheggen, Inge, additional, Kulagin, Alexander, additional, Tjon, Jennifer M-L., additional, Fattizzo, Bruno, additional, Ingram, Wendy, additional, Zaidi, Uzma, additional, Desnica, Lana, additional, Giammarco, Sabrina, additional, Drozd-Sokolowska, Joanna, additional, Xicoy, Blanca, additional, Patriarca, Andrea, additional, Loschi, Michael, additional, Szmigielska-Kaplon, Anna, additional, Beier, Fabian, additional, Cignetti, Alessandro, additional, Drexler, Beatrice, additional, Gavriilaki, Eleni, additional, Lanza, Francesco, additional, Orvain, Corentin, additional, Risitano, Antonio Maria, additional, De la Camara, Rafael, additional, and De Latour, Régis Peffault, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Strategies are needed to support people with alcohol use disorder and alcohol-related liver disease to take part in randomised clinical trials: results from the MIRAGE pilot trial of functional imagery training
- Author
-
Dhanda, Ashwin, primary, Allgar, Victoria, additional, Andrade, Jackie, additional, Callaghan, Lynne, additional, Hudson, Benjamin, additional, Ingram, Wendy, additional, King, Angela, additional, Lavers, Victoria, additional, Lomax, Joe, additional, McCune, Anne, additional, Musicha, Crispin, additional, Parker, Richard, additional, Rollinson, Christopher, additional, and Creanor, Siobhan, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Longitudinal realist evaluation of the Dementia PersonAlised Care Team (D-PACT) intervention: protocol
- Author
-
Wheat, Hannah, primary, Weston, Lauren, additional, Oh, Tomasina M, additional, Morgan-Trimmer, Sarah, additional, Ingram, Wendy, additional, Griffiths, Sarah, additional, Sheaff, Rod, additional, Clarkson, Paul, additional, Medina-Lara, Antonieta, additional, Musicha, Crispin, additional, Spicer, Stuart, additional, Ukoumunne, Obioha, additional, Allgar, Victoria, additional, Creanor, Siobhan, additional, Clark, Michael, additional, Quinn, Cath, additional, Gude, Alex, additional, McCabe, Rose, additional, Batool, Saqba, additional, Smith, Lorna, additional, Richards, Debra, additional, Shafi, Hannah, additional, Warwick, Bethany, additional, Lasrado, Reena, additional, Hussain, Basharat, additional, Jones, Hannah, additional, Dalkin, Sonia, additional, Bate, Angela, additional, Sherriff, Ian, additional, Robinson, Louise, additional, and Byng, Richard, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Testing the feasibility of a new intervention to help people with Parkinson's live well with anxiety
- Author
-
Lovegrove, Chris, primary, Marsden, Jon, additional, and Ingram, Wendy, additional
- Published
- 2023
- Full Text
- View/download PDF
21. Pharmacokinetic and pharmcodynamic studies of apomorphine in the treatment of idiopathic Parkinson's disease
- Author
-
Ingram, Wendy Merewyn
- Subjects
610 ,Medicine - Abstract
There were two aspects to the study of apomorphine in the treatment of Parkinson' s disease: (i) a clinical pharmacokinetic-pharmacodynamic (PK-PD) study was designed and implemented in response to the challenges of apomorphine dose-titration in Parkinson's disease, and in view of the scarcity of available literature on the PK-PD relationships of apomorphine in Parkinson's disease, (ii) the PK(and tolerability)of apomorphine dosing using novel delivery/formulation combinations were explored in view of the inherent limitations associated with the conventional (ie. subcutaneous) route of administration of apomorphine (e.g. cutaneous nodule formation, needle-phobia). An HPLC assay was developed for the quantification of apomorphine in plasma, and stability issues relating to sample storage and assay were investigated. With regards to the first aspect of the research, simultaneous PK-PD modelling was performed, using an effect compartment model to account for counterclockwise hysteresis in a sub-group of patients. According to the traditional two-stage approach to data analysis, mean (standard deviation) clearance following subcutaneous bolus was 2.2 (0.5) L/kg/h, (apparent) volume of distribution was 1.9 (0.8) L/kg, absorption half-life was 4.1 (2.1) minutes and elimination half-life was 69.5 (21.1)minutes (n=7). Equilibration half-life was estimated for two patients at 8.3 and 16.5 minutes. Focus was given to investigating the relevance of a potential correlation (which had previously been identified using in-house pilot data) between post-distributional apomorphine PK and apomorphine-induced anti-parkinsonian response in patients with Parkinson's disease. It was hypothesised that this particular correlation may be of use in a dose-optimisation scheme. However it was demonstrated that, in the patients studied, the concept could not be applied to apomorphine dose-optimisation. The novel delivery systems under scrutiny were: (i) Britaject® (Britannia Pharmaceuticals Ltd.) apomorphine formulation administered subcutaneously using a needle-free (jet) injector (J-TIP®, National Medical Products Inc.), (ii) an intranasal apomorphine powder formulation delivered using a turbospin insufflator (CDFS), and (iii) an apomorphine hydrogel co-polymer produced as a dosage-form for buccal delivery (Controlled Therapeutics (Scotland) Ltd.). As a result of this work, a rationale for subsequent development of the novel systems was provided. Indeed, the needle-free and buccal systems were, in their existing format, shown not to convey a net advantage over the existing system. However the intranasal formulation, with a mean (standard deviation) relative bioavailability of 41 (18)% (n=16) compared to subcutaneous bolus administration (and with a favourable outcome as regards to tolerability), was considered to be potentially suitable for further development.
- Published
- 2001
22. Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells
- Author
-
Vinci, Mara, Burford, Anna, Molinari, Valeria, Kessler, Ketty, Popov, Sergey, Clarke, Matthew, Taylor, Kathryn R., Pemberton, Helen N., Lord, Christopher J., Gutteridge, Alice, Forshew, Tim, Carvalho, Diana, Marshall, Lynley V., Qin, Elizabeth Y., Ingram, Wendy J., Moore, Andrew S., Ng, Ho-Keung, Trabelsi, Saoussen, H’mida-Ben Brahim, Dorra, Entz-Werle, Natacha, Zacharoulis, Stergios, Vaidya, Sucheta, Mandeville, Henry C., Bridges, Leslie R., Martin, Andrew J., Al-Sarraj, Safa, Chandler, Christopher, Sunol, Mariona, Mora, Jaume, de Torres, Carmen, Cruz, Ofelia, Carcaboso, Angel M., Monje, Michelle, Mackay, Alan, and Jones, Chris
- Published
- 2018
- Full Text
- View/download PDF
23. Supplementary Figure 2 from Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
- Author
-
Keating, Joanna, primary, Tsoli, Maria, primary, Hallahan, Andrew R., primary, Ingram, Wendy J., primary, Haber, Michelle, primary, and Ziegler, David S., primary
- Published
- 2023
- Full Text
- View/download PDF
24. Data from Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
- Author
-
Keating, Joanna, primary, Tsoli, Maria, primary, Hallahan, Andrew R., primary, Ingram, Wendy J., primary, Haber, Michelle, primary, and Ziegler, David S., primary
- Published
- 2023
- Full Text
- View/download PDF
25. Supplementary Tables 1 - 3, Figure Legend from Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
- Author
-
Keating, Joanna, primary, Tsoli, Maria, primary, Hallahan, Andrew R., primary, Ingram, Wendy J., primary, Haber, Michelle, primary, and Ziegler, David S., primary
- Published
- 2023
- Full Text
- View/download PDF
26. Supplementary Figure 1 from Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
- Author
-
Keating, Joanna, primary, Tsoli, Maria, primary, Hallahan, Andrew R., primary, Ingram, Wendy J., primary, Haber, Michelle, primary, and Ziegler, David S., primary
- Published
- 2023
- Full Text
- View/download PDF
27. Effectiveness and cost‐effectiveness of behavioural support for prolonged abstinence for smokers wishing to reduce but not quit: Randomised controlled trial of physical activity assisted reduction of smoking (TARS)
- Author
-
Taylor, Adrian H., primary, Thompson, Tom P., additional, Streeter, Adam, additional, Chynoweth, Jade, additional, Snowsill, Tristan, additional, Ingram, Wendy, additional, Ussher, Michael, additional, Aveyard, Paul, additional, Murray, Rachael L., additional, Harris, Tess, additional, Callaghan, Lynne, additional, Green, Colin, additional, Greaves, Colin J., additional, Price, Lisa, additional, and Creanor, Siobhan, additional
- Published
- 2023
- Full Text
- View/download PDF
28. A randomised controlled trial comparing the effectiveness of tai chi alongside usual care with usual care alone on the postural balance of community-dwelling people with dementia: protocol for the TACIT trial (TAi ChI for people with demenTia)
- Author
-
Nyman, Samuel R., Hayward, Christopher, Ingram, Wendy, Thomas, Peter, Thomas, Sarah, Vassallo, Michael, Raftery, James, Allen, Helen, and Barrado-Martín, Yolanda
- Published
- 2018
- Full Text
- View/download PDF
29. High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML
- Author
-
Othman, Jad, primary, Potter, Nicola, additional, Mokretar, Katya, additional, Taussig, David, additional, Khan, Anjum, additional, Krishnamurthy, Pramila, additional, Latif, Anne-Louise, additional, Cahalin, Paul, additional, Aries, James, additional, Amer, Mariam, additional, Belsham, Edward, additional, Conneally, Eibhlin, additional, Craddock, Charles, additional, Culligan, Dominic, additional, Dennis, Mike, additional, Duncan, Caroline, additional, Furness, Caroline, additional, Gkreka, Paraskevi, additional, Hodgson, Katherine, additional, Ingram, Wendy, additional, King, Andrew, additional, Kottaridis, Panagiotis, additional, McMullin, Mary Frances, additional, Mohite, Unmesh, additional, Ngu, Loretta, additional, Patrick, Katharine, additional, Rider, Tom, additional, Roberts, Wing, additional, Severinsen, Marianne Tang, additional, Storrar, Neill, additional, Taylor, Tom, additional, Russell, Nigel H., additional, and Dillon, Richard, additional
- Published
- 2022
- Full Text
- View/download PDF
30. A Film: 'Breaking the Stigma' An evidence-based approach to combat stigma around mental health struggles in academia
- Author
-
Wilson-Montemayor, Sarah, Devendorf, Andrew, Bankston, Adriana, Gazda, Małgorzata Anna, Linda C Corcoran, Rodriguez Chavez, Cesar, Vvedenskaya, Olga, and Ingram, Wendy Marie
- Abstract
Purpose Academics are more likely to suffer from mental health disorders such as depression and anxiety yet are less likely to seek treatment. Stigma is one of the highest ranked barriers to help-seeking for mental health problems. Strikingly, however, there is limited data on interventions to improve mental health outcomes in academia by decreasing mental health-related stigma despite the prevalence and impact of mental health issues on academic performance and lifestyle. Design Here we report a study conducted by Dragonfly Mental Health (DMH) at the University of California Berkeley in the Molecular and Cell Biology Department to assess the effectiveness of first-person narratives in decreasing mental health stigma. For this study, personal stories of 6 local faculty with lived experience of mental health struggles were shown in a short film during three separate divisional retreats. The audience members were then anonymously surveyed after the screening. Results The screening of the film was deemed beneficial by an overwhelming majority of participants, both with respect to reducing stigma and by fostering conversations about mental health culture. Implications This data suggests that sharing faculty stories is a powerful mechanism to reduce stigma, promote more open communication, and foster change in academic culture around mental health issues., This document is part of the Book of Abstracts of the ReMO 2022 Conference that was organized within the framework of COST Action CA19117 - "Researcher Mental Health".
- Published
- 2023
- Full Text
- View/download PDF
31. Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma
- Author
-
Noriega, Victor, Kaur, Harpreet, Devereux, Stephen, Byrne, Jennifer, Marcus, Robert, Haynes, Andrew, Yallop, Deborah, McMillan, Andrew, Ingram, Wendy, Khan, Anjum, Kenyon, Michelle, Potter, Victoria, Russell, Nigel, Mufti, Ghulam J., and Pagliuca, Antonio
- Published
- 2014
- Full Text
- View/download PDF
32. FLT3inhibitors as MRD-guided salvage treatment for molecular failure in FLT3mutated AML
- Author
-
Othman, Jad, Potter, Nicola, Mokretar, Katya, Taussig, David, Khan, Anjum, Krishnamurthy, Pramila, Latif, Anne-Louise, Cahalin, Paul, Aries, James, Amer, Mariam, Belsham, Edward, Conneally, Eibhlin, Craddock, Charles, Culligan, Dominic, Dennis, Mike, Duncan, Caroline, Freeman, Sylvie D., Furness, Caroline, Gilkes, Amanda, Gkreka, Paraskevi, Hodgson, Katherine, Ingram, Wendy, Jain, Manish, King, Andrew, Knapper, Steven, Kottaridis, Panagiotis, McMullin, Mary Frances, Mohite, Unmesh, Ngu, Loretta, O’Nions, Jenny, Patrick, Katharine, Rider, Tom, Roberts, Wing, Severinsen, Marianne Tang, Storrar, Neill, Taylor, Tom, Russell, Nigel H., and Dillon, Richard
- Abstract
Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR and those destined to relapse can be identified by high or rising levels of MRD, called molecular failure. This provides a window for pre-emptive intervention, but there is little evidence to guide treatment. The use of FLT3inhibitors (FLT3i) appears attractive but their use has not yet been evaluated. We identified 56 patients treated with FLT3i at molecular failure. The FLT3mutation was an ITD in 52, TKD in 7 and both in 3. Over half of patients had previously received midostaurin. Molecular failure occurred at a median 9.2 months from diagnosis and was treated with gilteritinib (n= 38), quizartinib (n= 7) or sorafenib (n= 11). 60% achieved a molecular response, with 45% reaching MRD negativity. Haematological toxicity was low, and 22 patients were bridged directly to allogeneic transplant with another 6 to donor lymphocyte infusion. 2-year overall survival was 80% (95%CI 69–93) and molecular event-free survival 56% (95%CI 44–72). High-sensitivity next-generation sequencing for FLT3-ITD at molecular failure identified patients more likely to benefit. FLT3i monotherapy for molecular failure is a promising strategy which merits evaluation in prospective studies.
- Published
- 2023
- Full Text
- View/download PDF
33. Multicentre, randomised controlled feasibility study to compare a 10-week physiotherapy programme using an interactive exercise training device to improve walking and balance, to usual care of children with cerebral palsy aged 4–18 years: the ACCEPT study protocol
- Author
-
Rapson, Rachel, primary, Marsden, Jonathan, additional, Latour, Jos, additional, Ingram, Wendy, additional, Stevens, Kara Nicola, additional, Cocking, Laura, additional, and Carter, Bernie, additional
- Published
- 2022
- Full Text
- View/download PDF
34. National Network of Depression Centers' Recommendations on Harmonizing Clinical Documentation of Electroconvulsive Therapy
- Author
-
Zandi, Peter P., primary, Morreale, Michael, additional, Reti, Irving M., additional, Maixner, Daniel F., additional, McDonald, William M., additional, Patel, Paresh D., additional, Achtyes, Eric, additional, Bhati, Mahendra T., additional, Carr, Brent R., additional, Conroy, Susan K., additional, Cristancho, Mario, additional, Dubin, Marc J., additional, Francis, Andrew, additional, Glazer, Kara, additional, Ingram, Wendy, additional, Khurshid, Khurshid, additional, McClintock, Shawn M., additional, Pinjari, Omar F., additional, Reeves, Kevin, additional, Rodriguez, Nelson F., additional, Sampson, Shirlene, additional, Seiner, Stephen J., additional, Selek, Salih, additional, Sheline, Yvette, additional, Smetana, Roy W., additional, Soda, Takahiro, additional, Trapp, Nicholas T., additional, Wright, Jesse H., additional, Husain, Mustafa, additional, and Weiner, Richard D., additional
- Published
- 2022
- Full Text
- View/download PDF
35. Additional file 2 of A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol
- Author
-
Swancutt, Dawn, Tarrant, Mark, Ingram, Wendy, Baldrey, Sarah, Burns, Lorna, Byng, Richard, Calitri, Raff, Creanor, Siobhan, Dean, Sarah, Evans, Lucy, Gill, Laura, Goodwin, Elizabeth, Hawkins, Lily, Hayward, Chris, Hind, Sarah, Hollands, Laura, Hosking, Joanne, Lloyd, Jenny, Moghadam, Shokraneh, Neilens, Helen, O’Kane, Mary, Perry, Steve, Sheaff, Rod, Spencer, Anne, Taylor, Adrian, Ward, Thomas, Watkins, Ross, Wilding, John, and Pinkney, Jonathan
- Abstract
Additional file 2. SPIRIT 2013 checklist.
- Published
- 2022
- Full Text
- View/download PDF
36. Additional file 1 of A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol
- Author
-
Swancutt, Dawn, Tarrant, Mark, Ingram, Wendy, Baldrey, Sarah, Burns, Lorna, Byng, Richard, Calitri, Raff, Creanor, Siobhan, Dean, Sarah, Evans, Lucy, Gill, Laura, Goodwin, Elizabeth, Hawkins, Lily, Hayward, Chris, Hind, Sarah, Hollands, Laura, Hosking, Joanne, Lloyd, Jenny, Moghadam, Shokraneh, Neilens, Helen, O’Kane, Mary, Perry, Steve, Sheaff, Rod, Spencer, Anne, Taylor, Adrian, Ward, Thomas, Watkins, Ross, Wilding, John, and Pinkney, Jonathan
- Abstract
Additional file 1. Tabulated summary of feasibility outcomes.
- Published
- 2022
- Full Text
- View/download PDF
37. Transitive Homology-Guided Structural Studies Lead to Discovery of Cro Proteins with 40% Sequence Identity but Different Folds
- Author
-
Roessler, Christian G., Hall, Branwen M., Anderson, William J., Ingram, Wendy M., Roberts, Sue A., Montfort, William R., and Cordes, Matthew H. J.
- Published
- 2008
- Full Text
- View/download PDF
38. A Novel Strategy to Identify Haematology Patients at High Risk of Developing Aspergillosis
- Author
-
Griffiths, James S., primary, White, P. Lewis, additional, Thompson, Aiysha, additional, da Fonseca, Diogo M., additional, Pickering, Robert J., additional, Ingram, Wendy, additional, Wilson, Keith, additional, Barnes, Rosemary, additional, Taylor, Philip R., additional, and Orr, Selinda J., additional
- Published
- 2021
- Full Text
- View/download PDF
39. A group-based programme for weight management (PROGROUP) versus usual care for weight management in adults with severe obesity
- Author
-
Ingram, Wendy, primary and Swancutt, Dawn, additional
- Published
- 2021
- Full Text
- View/download PDF
40. Toxoplasma gondii infection-induced Loss of Innate Aversion to Cat Urine in Mice
- Author
-
Ingram, Wendy Marie
- Subjects
Molecular biology ,Behavioral psychology ,Immunology ,Behavioral neuroimmunology ,Mouse innate behavior ,Parasite manipulation ,Toxoplasma gondii - Abstract
Toxoplasma gondii infection-induced Loss of Innate Aversion to Cat Urine in MicebyWendy Marie IngramDoctor of Philosophy in Molecular & Cell BiologyUniversity of California, BerkeleyProfessor Ellen Robey, Co-chairProfessor Michael Eisen, Co-chairToxoplasma gondii chronic infection in rodent secondary hosts has been reported to lead to a loss of innate, hard-wired fear toward cats, its primary host. However the generality of this response across T. gondii strains and the underlying mechanism for this pathogen-mediated behavioral change remains unknown. To begin exploring these questions, we evaluated the effects of infection with two previously uninvestigated isolates from the three major North American clonal lineages of T. gondii, Type III and an attenuated strain of Type I. Using an hour-long open field activity assay optimized for this purpose, we measured mouse aversion toward predator and non-predator urines. We show that loss of innate aversion of cat urine is a general trait caused by infection with any of the three major clonal lineages of parasite. Surprisingly, we found that infection with the attenuated Type I parasite results in sustained loss of aversion at times post infection when neither parasite nor ongoing brain inflammation were detectable. This suggests that T. gondii-mediated interruption of mouse innate aversion toward cat urine may occur during early acute infection in a permanent manner, not requiring persistence of parasite cysts or continuing brain inflammation. We investigated the role of the mouse immune system in this behavior manipulation and identify that interleukin 4 (IL4) is a key molecule required for the loss of innate aversion to cat urine. Characterization of the source of IL4 in mice following infection has revealed that there are a number of cell types from which the critical IL4 could be produced. Initial T cell transfer experiments suggest that CD4 T cells capable of making IL4 may be partially involved in mediating the behavior manipulation.
- Published
- 2015
41. Randomised controlled trial of an augmented exercise referral scheme using web-based behavioural support for inactive adults with chronic health conditions: the e-coachER trial
- Author
-
Taylor, Adrian, Taylor, Rod S, Ingram, Wendy, Dean, Sarah Gerard, Jolly, Kate, Mutrie, Nanette, Lambert, Jeff, Yardley, Lucy, Streeter, Adam, Greaves, Colin, McAdam, Chloe, Price, Lisa, Anokye, Nana Kwame, and Campbell, John
- Subjects
Adult ,Male ,diabetes mellitus type 2 ,obesity ,hypertension ,Adolescent ,Health Behavior ,physical activity ,primary care ,Young Adult ,Behavior Therapy ,Humans ,Referral and Consultation ,Original Research ,Aged ,Internet ,Social Support ,Middle Aged ,behaviour ,Exercise Therapy ,chronic ,accelerometer ,osteoarthritis ,Chronic Disease ,depression ,Female ,Physical and Mental Health ,internet ,Sedentary Behavior ,human activities - Abstract
Trial registration number ISRCTN15644451. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. Objective: To determine whether adding web-based support (e-coachER) to an exercise referral scheme (ERS) increases objectively assessed physical activity (PA). Design: Multicentre trial with participants randomised to usual ERS alone (control) or usual ERS plus e-coachER (intervention). Setting: Primary care and ERS in three UK sites from 2015 to 2018. Participants: 450 inactive ERS referees with chronic health conditions. Interventions: Participants received a pedometer, PA recording sheets and a user guide for the web-based support. e-coachER interactively encouraged the use of the ERS and other PA options. Main outcome measures: Primary and key secondary outcomes were: objective moderate-to-vigorous PA (MVPA) minutes (in ≥10 min bouts and without bouts), respectively, after 12 months. Secondary outcomes were: other accelerometer-derived and self-reported PA measures, ERS attendance, EQ-5D-5L, Hospital Anxiety and Depression Scale and beliefs about PA. All outcomes were collected at baseline, 4 and 12 months. Primary analysis was an intention to treat comparison between intervention and control arms at 12-month follow-up. Results: There was no significant effect of the intervention on weekly MVPA at 12 months between the groups recorded in ≥10 min bouts (mean difference 11.8 min of MVPA, 95% CI: -2.1 to 26.0; p=0.10) or without bouts (mean difference 13.7 min of MVPA, 95% CI: -26.8 to 54.2; p=0.51) for 232 participants with usable data. There was no difference in the primary or secondary PA outcomes at 4 or 12 months. Conclusion: Augmenting ERS referrals with web-based behavioural support had only a weak, non-significant effect on MVPA. Trial registration number: ISRCTN15644451. National Institute for Health Research (NIHR), Health Technology Assessment Programme (grant reference: 13/25/20).
- Published
- 2021
42. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes
- Author
-
Killick, Sally B., primary, Ingram, Wendy, additional, Culligan, Dominic, additional, Enright, Helen, additional, Kell, Jonathan, additional, Payne, Elspeth M., additional, Krishnamurthy, Pramila, additional, Kulasekararaj, Austin, additional, Raghavan, Manoj, additional, Stanworth, Simon J., additional, Green, Simone, additional, Mufti, Ghulam, additional, Quek, Lynn, additional, Cargo, Catherine, additional, Jones, Gail L., additional, Mills, Juliet, additional, Sternberg, Alex, additional, Wiseman, Daniel H., additional, and Bowen, David, additional
- Published
- 2021
- Full Text
- View/download PDF
43. The Use of Tranexamic Acid to Reduce the Need for Nasal Packing in Epistaxis (NoPAC): Randomized Controlled Trial
- Author
-
Reuben, Adam, primary, Appelboam, Andrew, additional, Stevens, Kara N., additional, Vickery, Jane, additional, Ewings, Paul, additional, Ingram, Wendy, additional, Jeffery, Alison N., additional, Body, Richard, additional, Hilton, Malcolm, additional, Coppell, Jason, additional, Wainman, Brian, additional, and Barton, Andy, additional
- Published
- 2021
- Full Text
- View/download PDF
44. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80
- Author
-
Hardwick, Nicola, Chan, Lucas, Ingram, Wendy, Mufti, Ghulam, and Farzaneh, Farzin
- Published
- 2010
- Full Text
- View/download PDF
45. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures
- Author
-
Ingram, Wendy, Kordasti, Shahram, Chan, Lucas, Barber, Linda D., Tye, Gee J., Hardwick, Nicola, Mufti, Ghulam J., and Farzaneh, Farzin
- Published
- 2009
- Full Text
- View/download PDF
46. A Human Dectin-2 Deficiency Associated With Invasive Aspergillosis
- Author
-
Griffiths, James S, primary, White, P Lewis, additional, Czubala, Magdalena A, additional, Simonazzi, Elena, additional, Bruno, Mariolina, additional, Thompson, Aiysha, additional, Rizkallah, Pierre J, additional, Gurney, Mark, additional, da Fonseca, Diogo M, additional, Naglik, Julian R, additional, Ingram, Wendy, additional, Wilson, Keith, additional, van de Veerdonk, Frank L, additional, Barnes, Rosemary, additional, Taylor, Philip R, additional, and Orr, Selinda J, additional
- Published
- 2021
- Full Text
- View/download PDF
47. A Film: 'Breaking the Stigma' An evidence-based approach to combat stigma around mental health struggles in academia
- Author
-
Ingram, Wendy Marie, Bankston, Adriana, Małgorzata, Anna Gazda, Corcoran, Linda C., Rodriguez Chavez, Cesar, Institut de biologie de l'ENS Paris (IBENS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département de Biologie - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Tilli, Nicolas, Institut de biologie de l'ENS Paris (UMR 8197/1024) (IBENS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Département de Biologie - ENS Paris
- Subjects
[SHS.INFO]Humanities and Social Sciences/Library and information sciences ,[SHS.INFO] Humanities and Social Sciences/Library and information sciences ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2020
48. FRI-418 - Strategies are needed to support people with alcohol use disorder and alcohol-related liver disease to take part in randomised clinical trials: results from the MIRAGE pilot trial of functional imagery training
- Author
-
Dhanda, Ashwin, Allgar, Victoria, Andrade, Jackie, Callaghan, Lynne, Hudson, Benjamin, Ingram, Wendy, King, Angela, Lavers, Victoria, Lomax, Joe, McCune, Anne, Musicha, Crispin, Parker, Richard, Rollinson, Christopher, and Creanor, Siobhan
- Published
- 2023
- Full Text
- View/download PDF
49. Adding web-based behavioural support to exercise referral schemes for inactive adults with chronic health conditions: the e-coachER Randomised Controlled Trial
- Author
-
Taylor, Adrian H., Taylor, Rod S., Ingram, Wendy M., Anokye, Nana, Dean, Sarah, Jolly, Kate, Mutrie, Nanette, Lambert, Jeffrey, Yardley, Lucy, Greaves, Colin, King, Jennie, McAdam, Chloe, Steele, Mary, Price, Lisa, Streeter, Adam, Charles, Nigel, Terry, Rohini, Webb, Douglas, Campbell, John, Hughes, Lucy, Ainsworth, Ben, Jones, Ben, Jane, Ben, Erwin, Jo, Little, Paul, Woolf, Anthony, and Cavanagh, Chris
- Subjects
HYPERTENSION ,Health Policy ,EXERCISE ,DEPRESSION ,E-HEALTH ,COST-EFFECTIVENESS ,ACCELEROMETER ,PRIMARY CARE ,SDG 3 - Good Health and Well-being ,OSTEOARTHRITIS ,OBESITY ,DIABETES - Abstract
BACKGROUND: There is modest evidence that exercise referral schemes increase physical activity in inactive individuals with chronic health conditions. There is a need to identify additional ways to improve the effects of exercise referral schemes on long-term physical activity. OBJECTIVES: To determine if adding the e-coachER intervention to exercise referral schemes is more clinically effective and cost-effective in increasing physical activity after 1 year than usual exercise referral schemes. DESIGN: A pragmatic, multicentre, two-arm randomised controlled trial, with a mixed-methods process evaluation and health economic analysis. Participants were allocated in a 1 : 1 ratio to either exercise referral schemes plus e-coachER (intervention) or exercise referral schemes alone (control). SETTING: Patients were referred to exercise referral schemes in Plymouth, Birmingham and Glasgow. PARTICIPANTS: There were 450 participants aged 16-74 years, with a body mass index of 30-40 kg/m2, with hypertension, prediabetes, type 2 diabetes, lower limb osteoarthritis or a current/recent history of treatment for depression, who were also inactive, contactable via e-mail and internet users. INTERVENTION: e-coachER was designed to augment exercise referral schemes. Participants received a pedometer and fridge magnet with physical activity recording sheets, and a user guide to access the web-based support in the form of seven 'steps to health'. e-coachER aimed to build the use of behavioural skills (e.g. self-monitoring) while strengthening favourable beliefs in the importance of physical activity, competence, autonomy in physical activity choices and relatedness. All participants were referred to a standard exercise referral scheme. PRIMARY OUTCOME MEASURE: Minutes of moderate and vigorous physical activity in ≥ 10-minute bouts measured by an accelerometer over 1 week at 12 months, worn ≥ 16 hours per day for ≥ 4 days including ≥ 1 weekend day. SECONDARY OUTCOMES: Other accelerometer-derived physical activity measures, self-reported physical activity, exercise referral scheme attendance and EuroQol-5 Dimensions, five-level version, and Hospital Anxiety and Depression Scale scores were collected at 4 and 12 months post randomisation. RESULTS: Participants had a mean body mass index of 32.6 (standard deviation) 4.4 kg/m2, were referred primarily for weight loss and were mostly confident self-rated information technology users. Primary outcome analysis involving those with usable data showed a weak indicative effect in favour of the intervention group (n = 108) compared with the control group (n = 124); 11.8 weekly minutes of moderate and vigorous physical activity (95% confidence interval -2.1 to 26.0 minutes; p = 0.10). Sixty-four per cent of intervention participants logged on at least once; they gave generally positive feedback on the web-based support. The intervention had no effect on other physical activity outcomes, exercise referral scheme attendance (78% in the control group vs. 75% in the intervention group) or EuroQol-5 Dimensions, five-level version, or Hospital Anxiety and Depression Scale scores, but did enhance a number of process outcomes (i.e. confidence, importance and competence) compared with the control group at 4 months, but not at 12 months. At 12 months, the intervention group incurred an additional mean cost of £439 (95% confidence interval -£182 to £1060) compared with the control group, but generated more quality-adjusted life-years (mean 0.026, 95% confidence interval 0.013 to 0.040), with an incremental cost-effectiveness ratio of an additional £16,885 per quality-adjusted life-year. LIMITATIONS: A significant proportion (46%) of participants were not included in the primary analysis because of study withdrawal and insufficient device wear-time, so the results must be interpreted with caution. The regression model fit for the primary outcome was poor because of the considerable proportion of participants [142/243 (58%)] who recorded no instances of ≥ 10-minute bouts of moderate and vigorous physical activity at 12 months post randomisation. FUTURE WORK: The design and rigorous evaluation of cost-effective and scalable ways to increase exercise referral scheme uptake and maintenance of moderate and vigorous physical activity are needed among patients with chronic conditions. CONCLUSIONS: Adding e-coachER to usual exercise referral schemes had only a weak indicative effect on long-term rigorously defined, objectively assessed moderate and vigorous physical activity. The provision of the e-coachER support package led to an additional cost and has a 63% probability of being cost-effective based on the UK threshold of £30,000 per quality-adjusted life-year. The intervention did improve some process outcomes as specified in our logic model. TRIAL REGISTRATION: Current Controlled Trials ISRCTN15644451. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 63. See the NIHR Journals Library website for further project information.
- Published
- 2019
50. Randomised controlled trial of the effect of Tai Chi on postural balance of people with dementia
- Author
-
Nyman, Samuel R, Ingram, Wendy, Sanders, Jeanette, Thomas, Peter W, Thomas, Sarah, Vassallo, Michael, Raftery, James, Bibi, Iram, and Barrado-Martín, Yolanda
- Subjects
Aged, 80 and over ,Male ,exercise ,clinical trial ,Clinical Interventions in Aging ,Time and Motion Studies ,Quality of Life ,Humans ,Dementia ,Female ,Tai Ji ,Independent Living ,accidental falls ,Postural Balance ,intervention ,Aged ,Original Research ,cognitive impairment - Abstract
Purpose To investigate the effect of Tai Chi exercise on postural balance among people with dementia (PWD) and the feasibility of a definitive trial on falls prevention. Patients and methods Dyads, comprising community-dwelling PWD and their informal carer (N=85), were randomised to usual care (n=43) or usual care plus weekly Tai Chi classes and home practice for 20 weeks (n=42). The primary outcome was the timed up and go test. All outcomes for PWD and their carers were assessed six months post-baseline, except for falls, which were collected prospectively over the six-month follow-up period. Results For PWD, there was no significant difference at follow-up on the timed up and go test (mean difference [MD] = 0.82, 95% confidence interval [CI] = −2.17, 3.81). At follow-up, PWD in the Tai Chi group had significantly higher quality of life (MD = 0.051, 95% CI = 0.002, 0.100, standardised effect size [ES] = 0.51) and a significantly lower rate of falls (rate ratio = 0.35, 95% CI =0.15, 0.81), which was no longer significant when an outlier was removed. Carers in the Tai Chi group at follow-up were significantly worse on the timed up and go test (MD = 1.83, 95% CI = 0.12, 3.53, ES = 0.61). The remaining secondary outcomes were not significant. No serious adverse events were related to participation in Tai Chi. Conclusion With refinement, this Tai Chi intervention has potential to reduce the incidence of falls and improve quality of life among community-dwelling PWD [Trial registration: NCT02864056]., Video abstract Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/4mLW1DbeYVw
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.